[1]李万婷,刘海燕,秦丽军,等.99Tcm-3PRGD2整合素受体显像鉴别乳腺良恶性病变的价值及与超声检查的对比研究[J].国际放射医学核医学杂志,2018,(3):242-247.[doi:10.3760/cma.j.issn.1673-4114.2018.03.009]
 Li Wanting,Liu Haiyan,Qin Lijun,et al.The evaluation of 99Tcm-3PRGD2 integrin receptor imaging in the differential diagnosis in benign and malignant breast lesions comparision with ultrasound[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(3):242-247.[doi:10.3760/cma.j.issn.1673-4114.2018.03.009]
点击复制

99Tcm-3PRGD2整合素受体显像鉴别乳腺良恶性病变的价值及与超声检查的对比研究(/HTML)
分享到:

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
期数:
2018年第3期
页码:
242-247
栏目:
临床研究
出版日期:
2018-05-25

文章信息/Info

Title:
The evaluation of 99Tcm-3PRGD2 integrin receptor imaging in the differential diagnosis in benign and malignant breast lesions comparision with ultrasound
作者:
李万婷1 刘海燕1 秦丽军3 崔雅丽1 牛静1 武志芳1 刘静2 张国琛4 任媛3 李思进1
1. 030001 太原, 山西医科大学第一医院核医学科;
2. 030001 太原, 山西医科大学第一医院普外科;
3. 030001 太原, 山西省肿瘤医院核医学科;
4. 030001 太原, 山西省肿瘤医院乳腺科
Author(s):
Li Wanting1 Liu Haiyan1 Qin Lijun3 Cui Yali1 Niu Jing1 Wu Zhifang1 Liu Jing2 Zhang Guochen4 Ren Yuan3 Li Sijin1
1. Department of Nuclear Medicine, the First Hospital of Shanxi Medical University, Taiyuan 030001, China;
2. Department of General Surgery, the First Hospital of Shanxi Medical University, Taiyuan 030001, China;
3. Department of Nuclear Medicine, Tumor Hospital of Shanxi Medical University, Taiyuan 030001, China;
4. Department of Breast Surgery, Tumor Hospital of Shanxi Medical University, Taiyuan 030001, China
关键词:
乳腺肿瘤单光子发射计算机体层摄影术超声检查整合素αvβ3受体
Keywords:
Breast neoplasmsSingle photon emission computed tomography computed tomographyUltrasonographyIntegrin αvβ3 receptor
DOI:
10.3760/cma.j.issn.1673-4114.2018.03.009
摘要:
目的 探讨99Tcm-3PRGD2整合素受体显像鉴别乳腺良恶性病变的价值及与超声检查的对比研究。方法 收集2016年10月至2017年6月因乳腺结节或肿块拟行穿刺或手术治疗的女性患者,行乳腺超声检查,选取超声提示病灶直径>1 cm的45例患者经肘静脉注射99Tcm-3PRGD2(740~925 MBq)后行早期15 min SPECT静态显像及2 h SPECT/CT俯卧位显像。以病理结果为“金标准”,采用半定量分析指标T/NT值建立诊断阈值并进行诊断效能分析。组间比较采用独立样本非参数检验Mann-Whitney U方法;诊断效能比较采用χ2检验。结果 45例患者经病理学检查共发现56个病灶,其中,35个病灶为乳腺癌,21个病灶为良性病变。99Tcm-3PRGD2 2 h SPECT/CT显像的乳腺恶性病灶T/NT值(3.92±1.67)高于良性病灶T/NT值(2.04±0.46),且差异有统计学意义(Z=-3.77,P=0.00)。取约登指数最大时的临界值2.9,99Tcm-3PRGD2 SPECT/CT显像的灵敏度、特异度、准确率分别为82.9%、71.4%、78.6%,诊断乳腺良恶性病变受试者工作特征(ROC)曲线下面积为0.77;超声诊断乳腺良恶性病变ROC曲线下面积为0.76,其灵敏度、特异度、准确率分别为85.7%、66.7%、78.6%。99Tcm-3PRGD2 SPECT/CT与超声诊断效能相近(χ2=0.05,P>0.05)。超声+99Tcm-3PRGD2 SPECT/CT联合检查可提高乳腺良恶性诊断的准确率(92.9%),分别与二者比较差异均有统计学意义(χ2=77.17、74.87,均P<0.05)。结论 99Tcm-3PRGD2整合素受体显像可以从肿瘤血管生成角度鉴别乳腺良恶性病变,提供解剖及功能信息,尤其对于超声声像图表现不典型时,可进一步鉴别良恶性,减少患者不必要的穿刺等有创性检查。
Abstract:
Objective To evaluate the diagnostic efficacy of 99Tcm-3PRGD2 integrin receptor imaging in the differential diagnosis of benign and malignant lesions in comparison with ultrasound. Methods Forty-five females(53.0±9.5 years old) with breast nodules or masses measuring over 1 cm from October 2016 to June 2017, which were diagnosed through ultrasound, underwent early imaging via 99Tcm-3PRGD2 (740-925 MBq) for 15 min and then SPECT/CT in prone position after 2 h. The pathology was the gold standard. Then, a semi-quantitative method was used to evaluate the values of 99Tcm-3PRGD2 integrin receptor imaging of breast lesions and compare them with ultrasound results. The Mann-Whitney U test was used to compare the groups. Lastly, diagnostic efficacy was compared using a chi-square test. Results 99Tcm-3PRGD2 integrin receptor imaging identified 56 lesions in 45 patients, 35 of which were malignant and 21 were benign. The T/NT values of the malignant lesions were significantly higher than those of the benign lesions(Z=-3.77, P=0.00) in the SPECT/CT images. The sensitivity, specificity, and accuracy of 99Tcm-3PRGD2 and ultrasound were 82.9%, 71.4%, and 78.6%, and 85.7%, 66.7%, and 78.6%, respectively. The critical value was 2.9 with the maximal Youden index. Furthermore, areas under the ROC curve for 99Tcm-3PRGD2 and ultrasound were 0.77 and 0.76, respectively. The diagnostic efficacy of 99Tcm-3PRGD2 was similar to that of ultrasonography(χ2=0.05, P>0.05). Thus, combining the two methods can improve the accuracy of diagnosis(92.9%) compare with ultrasound and 99Tcm-3PRGD2 (χ2=77.14, 74.87, all P<0.05). Conclusions 99Tcm-3PRGD2 integrin receptor imaging can identify benign and malignant breast lesions from an angiogenesis perspective with anatomical and functional information. Moreover, this technique can further identify benign and malignant lesions to reduce unnecessary punctures when ultrasonograms are unavailable.

参考文献/References:

[1] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. DOI:10.3322/caac.21338.
[2] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108. DOI:10.3322/caac.21262.
[3] DeSantis C, Ma J, Bryan L, et al. Breast cancer statistics, 2013[J]. CA Cancer J Clin, 2014, 64(1):52-62. DOI:10.3322/caac.21203.
[4] Pysz MA, Gambhir SS, Willmann JK. Molecular imaging:current status and emerging strategies[J]. Clin Radiol, 2010, 65(7):500-516. DOI:10.1016/j.crad.2010.03.011.
[5] Wang X, Feng H, Zhao S, et al. SPECT and PET radiopharmaceuticals for molecular imaging of apoptosis:from bench to clinic[J]. Oncotarget, 2017, 8(12):20476-20495. DOI:10.18632/oncotarget.14730.
[6] Meng Q, Li Z. Molecular imaging probes for diagnosis and therapy evaluation of breast cancer[J]. Int J Biomed Imaging, 2013, 2013:230487. DOI:10.1155/2013/230487.
[7] Niu G, Chen X. Why integrin as a primary target for imaging and therapy[J]. Theranostics, 2011(1):30-47.
[8] Wang F, Li Y, Shen Y, et al. The functions and applications of RGD in tumor therapy and tissue engineering[J]. Int J Mol Sci, 2013, 14(7):13447-13462. DOI:10.3390/ijms140713447.
[9] Liu L, Song Y, Gao S, et al. 99Tcm-3PRGD2 scintimammography in palpable and nonpalpable breast lesions[J]. Mol Imaging, 2014, 13(5):1-7. DOI:10.2310/7290.2014.00010.
[10] Chen Q, Ma Q, Chen M, et al. An exploratory study on 99mTc-RGD-BBN peptide scintimammography in the assessment of breast malignant lesions compared to 99mTc-3P4-RGD2[J/OL]. PLoS One, 2015, 10(4):e0123401[2017-11-15]. http://journals.plos.org/plosone/article?id=10.1371/journal.pone. 0123401. DOI:10.1371/journal.pone.0123401.
[11] Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer:current progress, unresolved questions and future directions[J]. Angiogenesis, 2014, 17(3):471-494. DOI:10.1007/s10456-014-9420-y.
[12] Bohl CR, Harihar S, Denning WL, et al. Metastasis suppressors in breast cancers:mechanistic insights and clinical potential[J]. J Mol Med (Berl), 2014, 92(1):13-30. DOI:10.1007/s00109-013-1109-y.
[13] Brooks SA, Lomax-Browne HJ, Carter TM, et al. Molecular interactions in cancer cell metastasis[J]. Acta Histochem, 2010, 112(1):3-25. DOI:10.1016/j.acthis.2008.11.022.
[14] Haubner RH, Wester HJ, Weber WA, et al. Radiotracer-based strategies to image angiogenesis[J]. Q J Nucl Med, 2003, 47(3):189-199.
[15] 陈贵兵, 欧阳忠, 韩成坤, 等. 99Tcm-3PRGD2整合素受体显像在乳腺癌定性诊断中的价值及与钼靶检查的对比研究[J]. 国际放射医学核医学杂志, 2017, 41(1):1-7. DOI:10.3760/cma.j.issn.1673-4114.2017.01.001. Chen GB, Ouyang Z, Han CK, et al. Evaluation of 99Tcm-3PRGD2 integrin receptor imaging in qualitative diagnosis of breast cancer and its comparison with mammography[J]. Int J Radiat Med Nucl Med, 2017, 41(1):1-7.
[16] Pichler BJ, Kneilling M, Haubner R, et al. Imaging of delayed-type hypersensitivity reaction by PET and 18F-galacto-RGD[J]. J Nucl Med, 2005, 46(1):184-189.
[17] McDonald DM, Choyke PL. Imaging of angiogenesis:from microscope to clinic[J]. Nat Med, 2003, 9(6):713-725. DOI:10.1038/nm0603-713.
[18] Chen G, Ouyang Z, Wang F, et al. Evaluation of Tc-99m-3PRGD2 Integrin Receptor Imaging in the Differential Diagnosis of Breast Lesions and Comparison With Mammography[J]. Cancer Invest, 2017, 35(2):108-115. DOI:10.1080/07357907.2016.1270957.
[19] Cochet A, Pigeonnat S, Khoury B, et al. Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET/CT:comparison with angiogenesis markers and prognostic factors[J]. J Nucl Med, 2012, 53(4):512-520. DOI:10.2967/jnumed.111.096834.

相似文献/References:

[1]杨雷,袁卫红,王家平,等.99Tcm-MIBI显像与钼靶X线对乳腺癌诊断的比较研究[J].国际放射医学核医学杂志,2016,40(2):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
 Yang Lei,Yuan Weihong,Wang Jiaping,et al.Diagnostic value of technetium 99Tcm sestamibi and X-ray mammography in breast cancer: a comparison study[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
[2]马乐,张万春,李晓敏.乳腺癌前哨淋巴结核素显像新进展[J].国际放射医学核医学杂志,2016,40(2):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
 Ma Le,Zhang Wanchun,Li Xiaomin.Evolution of radionuclide imaging of sentinel node lymphscintigraphy in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
[3]储小飞,赵舒怡,樊赛军.肿瘤干细胞与辐射抗性的研究进展[J].国际放射医学核医学杂志,2015,39(5):431.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 019]
 chu xiaofei,zhao shuyi,fan saijun..advance progress of cancer stem cells and radioresistance[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):431.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 019]
[4]陈伟君,孙达.99Tcm-MIBI显像在乳腺癌新辅助化疗中的应用价值[J].国际放射医学核医学杂志,2015,39(6):487.[doi:10.3760/cma.j.issn.1673-4114.2015.06.011]
 Chen Weijun,Sun Da.Clinical value of 99Tcm-MIBI imaging in neoadjuvant chemotherapy of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):487.[doi:10.3760/cma.j.issn.1673-4114.2015.06.011]
[5]胡鸿,唐刚华,聂大红.乳腺癌分子显像研究进展[J].国际放射医学核医学杂志,2015,39(1):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
 Hu Hong,Tang Ganghua,Nie Dahong.Progress on molecular imaging of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
[6]黄娟,颜剑豪,梁联保,等.注射钆剂后弥散加权成像对乳腺肿瘤诊断的影响[J].国际放射医学核医学杂志,2015,39(4):287.[doi:10.3760/cma.j.issn.1673-4114.2015.04.003]
 Huang Juan,Yan Jianhao,Liang Lianbao,et al.Evaluation of the diffusion-weighted imaging after contrast for the characterization of breast tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):287.[doi:10.3760/cma.j.issn.1673-4114.2015.04.003]
[7]李雯,冯彦林.18F-FDG PET/CT评估三阴性乳腺癌新辅助化疗疗效的研究进展[J].国际放射医学核医学杂志,2014,38(3):197.[doi:10.3760/cma.j.issn.1673-4114.2014.03.013]
 Li Wen,Feng Yanlin.Advances of assessment with 18F-FDG PET/CT in triple-negative breast cancer during neoadjuvant chemotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):197.[doi:10.3760/cma.j.issn.1673-4114.2014.03.013]
[8]殷丽娜,张旭霞,张俊香,等.Wnt/β-catenin信号通路——乳腺癌的潜在治疗靶点[J].国际放射医学核医学杂志,2014,38(4):252.[doi:10.3760/cma.j.issn.1673-4114.2014.04.011]
 Yin Lina,Zhang Xuxia,Zhang Junxiang,et al.The Wnt/β-catenin signaling pathway-a potential therapeutic target of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):252.[doi:10.3760/cma.j.issn.1673-4114.2014.04.011]
[9]刘超,邓智勇,刘鹏杰,等.89SrCL2与唑来膦酸联合治疗乳腺癌转移性骨肿瘤的疗效分析[J].国际放射医学核医学杂志,2014,38(5):300.[doi:10.3760/cma.j.issn.1673-4114.2014.05.006]
 Liu Chao,Deng Zhi-yong,Liu Peng-jie,et al.Analysis on the curative effect of combination therapy with zoledronic acid and 89SrCL2 on bone tumor with breast cancer metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):300.[doi:10.3760/cma.j.issn.1673-4114.2014.05.006]
[10]胡梦裳,章斌.PET/CT显像在乳腺癌疗效评价及预后中的作用[J].国际放射医学核医学杂志,2014,38(5):332.[doi:10.3760/cma.j.issn.1673-4114.2014.05.013]
 Hu Meng-shang,Zhang Bin.The role of PET/CT imaging in the evaluation of the efficacy and prognosis of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):332.[doi:10.3760/cma.j.issn.1673-4114.2014.05.013]

备注/Memo

备注/Memo:
收稿日期:2017-11-16。
基金项目:山西省卫生和计划生育委员会课题(2015036);山西医科大学大学生创新创业项目(20170823)
通讯作者:刘海燕,Email:liuhaiyan-1203@126.com
更新日期/Last Update: 2018-05-25